×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Syros Pharmaceuticals Stock Forecast, Price & News

$0.91
-0.05 (-5.21%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.91
$0.98
50-Day Range
$0.69
$1.08
52-Week Range
$0.65
$5.70
Volume
221,376 shs
Average Volume
762,085 shs
Market Capitalization
$57.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Syros Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,504.4% Upside
$14.60 Price Target
Short Interest
Healthy
7.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.71) to ($1.91) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.34 out of 5 stars

Medical Sector

168th out of 1,428 stocks

Pharmaceutical Preparations Industry

73rd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals logo

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock News Headlines

Syros Pharmaceuticals Tops Q1 EPS by 7c
Syros Pharmaceuticals Q1 2022 Earnings Preview
Syros Pharmaceuticals Q4 2021 Earnings Preview
Syros Pharmaceuticals's Earnings: A Preview
Syros outlines clinical updates and 2022 goals
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
124
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$14.60
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+1,841.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-86.56 million
Net Margins
-403.99%
Pretax Margin
-403.99%

Debt

Sales & Book Value

Annual Sales
$23.49 million
Book Value
$1.38 per share

Miscellaneous

Free Float
55,344,000
Market Cap
$57.17 million
Optionable
Optionable
Beta
2.14














Syros Pharmaceuticals Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2022?

4 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' stock. Their SYRS stock forecasts range from $10.00 to $23.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $14.60 in the next year. This suggests a possible upside of 1,504.4% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Syros Pharmaceuticals' stock performed in 2022?

Syros Pharmaceuticals' stock was trading at $3.26 at the start of the year. Since then, SYRS stock has decreased by 72.1% and is now trading at $0.91.
View the best growth stocks for 2022 here
.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Syros Pharmaceuticals
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The firm had revenue of $5.47 million for the quarter, compared to analyst estimates of $4.56 million. Syros Pharmaceuticals had a negative net margin of 403.99% and a negative trailing twelve-month return on equity of 104.21%. During the same quarter in the previous year, the business earned ($0.23) earnings per share.
View Syros Pharmaceuticals' earnings history
.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian M.D., Pres, CEO & Director (Age 61, Pay $939.4k)
  • Dr. Richard A. Young Ph.D., Scientific Founder, Member of Scientific Advisory Board & Director (Age 68, Pay $50k)
  • Mr. Jason Haas, Chief Financial Officer (Age 54, Pay $457.22k)
  • Dr. David A. Roth M.D., Chief Medical Officer (Age 59, Pay $668.12k)
  • Dr. James E. Bradner M.D., Founder (Age 50)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Gerald E. Quirk Esq., J.D., Sr. Advisor (Age 54)
  • Dr. Eric R. Olson Ph.D., Chief Scientific Officer (Age 64)
  • Courtney Solberg, Mang. of Corp. Communications and Investor Relations
  • Dr. Christian C. Fritz Ph.D., Head of Biology

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $0.91.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $57.17 million and generates $23.49 million in revenue each year. The company earns $-86.56 million in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 124 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for Syros Pharmaceuticals is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.